Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 1.00 |
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Simeprevir SCHEMBL2229194 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18539068 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL6876363 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL829744 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465130 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL12445256 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465866 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL826061 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18537915 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL1070885 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-11572565-B2 | Inducible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-11530246-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220025381-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| US-20170360783-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3150596-A1 | AMORPHOUS SALT OF A MACROCYCLIC INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | CTSS 53/4885CTSB 54/4885ADRB3 3737/4885 |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSS 3754/4885CTSB 4535/4885ADRB3 4589/4885 |
| US-20170360783-A1 | Methods for Treating HCV | EIF2AK2, IFNG, IFNAR1 | CTSS 913/4885CTSB 359/4885ADRB3 1861/4885 |
| US-11530246-B2 | Regulated synthetic gene expression systems | SRRT, BPTF, MYCBP | CTSS 3754/4885CTSB 4535/4885ADRB3 4589/4885 |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSS 53/4885CTSB 54/4885ADRB3 3737/4885 |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSS 3754/4885CTSB 4535/4885ADRB3 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.